Vivid Dx
Develops AI healthcare solutions that help hospitals address drug-resistant infections, a major challenge in modern medicine.
Overview
Vivid Dx is an AI healthcare company focused on helping hospitals confront drug-resistant infections. Its offering is positioned for clinical providers facing antimicrobial resistance, described in its funding announcement as one of modern medicine’s most urgent threats. The company raised $15 million in an undisclosed round announced on July 28, 2026, representing its reported total funding across one round. The financing reflects investor interest in hospital-focused technologies for infection-related challenges.
Funding History
Vivid Dx Raises $15M to Help Hospitals Confront One of Modern Medicine's Most Urgent Threats: Drug-Resistant Infections
Frequently Asked Questions
- How much funding does AI Funding track for Vivid Dx?
- AI Funding tracks $15M for Vivid Dx across 1 funding round in this database.
- What does Vivid Dx do?
- Vivid Dx is an AI healthcare company focused on helping hospitals confront drug-resistant infections. Its offering is positioned for clinical providers facing antimicrobial resistance, described in its funding announcement as one of modern medicine’s most urgent threats. The company raised $15 million in an undisclosed round announced on July 28, 2026, representing its reported total funding across one round. The financing reflects investor interest in hospital-focused technologies for infection-related challenges.
- Where is Vivid Dx headquartered?
- Vivid Dx is headquartered in San Francisco, CA.
Related Insights
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $25.9 billion raised across 94 deals, with 14 mega-rounds capturing 79.8% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.
A deep comparison of Science Corp.'s neurotech-driven brain-computer interfaces and Nscale's AI cloud infrastructure, examining how $230M and $2B in recent funding fuel fundamentally different visions of artificial intelligence.